RecruitingRecruiting
A Study to Investigate the Efficacy and Safety of GSK5784283 (Felcorekibart) Compared With Placebo in Participants With Moderate to Very Severe COPD (PERSIST COPD-2)
NCT07780656 · GlaxoSmithKline
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST COPD-2)
About this study
The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.
Eligibility criteria
Inclusion Criteria:
* Male or eligible female participants.
* Participants with \>=40 to less than or equal to (\<=) 80 years of age.
* An eosinophilic phenotype with elevated BEC.
* Moderate to very severe COPD with frequent exacerbations.
* Participants with elevated COPD assessment test (CAT) score.
* Current or former cigarette smokers.
* On triple (Inhaled corticosteroid \[ICS\]+ Long-acting muscarinic antagonist \[LAMA\]+ Long-acting beta-agonist \[LABA\]) or dual inhaled COPD therapy, if ICS is considered not appropriate.
Exclusion Criteria:
* Current or prior physician diagnosis of asthma.
* Other clinically significant lung disease.
* Pneumonia, COPD exacerbation, or lower respiratory tract infection within the 4 weeks prior to Screening Visit 1.
* Participants with a history of, or plan for lung volume reduction surgery / endobronchial valve procedure.
* Continuous oxygen therapy (more than 16 hours/ day).
* Cor pulmonale resulting in right heart failure and severe pulmonary hypertension.
* A current malignancy or history of malignant neoplasm within the last 5 years (except definitively treated non-melanoma skin cancer or carcinoma in situ of the uterine cervix).
* Myocardial infarction, unstable angina or stroke within 6 months of screening, unstable arrhythmia.
* New York Heart Association class III or IV heart failure.
* Other significant medical conditions that could impact participants' safety or study outcomes.
Study design
Enrollment target: 624 participants
Allocation: randomized
Masking: quadruple
Age groups: adult, older_adult
Timeline
Starts: 2026-09-11
Estimated completion: 2030-03-15
Last updated: 2026-11-12
Interventions
Drug: GSK5784283Drug: PlaceboDrug: Standard of care
Primary outcomes
- • Annualized rate of moderate or severe COPD Exacerbations (Up to Week 78)
Sponsor
GlaxoSmithKline · industry
Contacts & investigators
ContactUS GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · 877-379-3718
ContactEU GSK Clinical Trials Call Center · contact · GSKClinicalSupportHD@gsk.com · +44 (0) 20 89904466
InvestigatorGSK Clinical Trials · study_director, GlaxoSmithKline
All locations (9)
GSK Investigational SiteRecruiting
Cape Coral, Florida, United States
GSK Investigational SiteRecruiting
Greenacres City, Florida, United States
GSK Investigational SiteRecruiting
Miami, Florida, United States
GSK Investigational SiteRecruiting
Tampa, Florida, United States
GSK Investigational SiteRecruiting
New York, New York, United States
GSK Investigational SiteRecruiting
Rapid City, South Dakota, United States
GSK Investigational SiteRecruiting
West Point, Utah, United States
GSK Investigational SiteRecruiting
Spokane, Washington, United States
GSK Investigational SiteRecruiting
Buenos Aires, Argentina